바이오테크 보도자료
-
- Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health
- Ferring Pharmaceuticals, Rebiotix Inc., a Ferring Company, and MyBiotics Pharma Ltd. today announced a multi-year strategic collaboration to develop live microbiota-based biotherapeutics to address bacterial...
- 2021년 02월 17일
-
- Thoma Bravo-Owned Quorum Software and Aucerna to Merge and Acquire TietoEVRY's Oil and Gas Software Business
- Quorum Software (“Quorum”), a world leader in digital transformation for the energy industry, today announced two major transactions that will result in the creation of the world's largest software provider ...
- 2021년 02월 16일
-
- Takeda’s Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in Transplant Recipients With Refractory, With or Without Resistance, Cytomegalovirus Infection/Disease
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today at the 2021 Transplantation & Cellular Therapy (TCT) Meetings Digital Experience announced new, late-breaking Phase 3 data from the ...
- 2021년 02월 15일
-
- Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn’s Disease
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has submitted an application to the Japanese Ministry of Health, Labour and Welfare to manufacture and market darv...
- 2021년 02월 15일
-
- Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn’s Disease
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has submitted an application to the Japanese Ministry of Health, Labour and Welfare to manufacture and market darv...
- 2021년 02월 10일
-
- MED™ 3D Printed Pharmaceutical Product Receives IND Clearance From the US FDA
- Triastek, Inc. (“Triastek”), a pharmaceutical company specializing in 3D printing of drug products, announced today that the United States Food and Drug Administration (FDA) has approved its Investigational ...
- 2021년 02월 10일
-
- Rhizen Pharmaceuticals AG Announces That Its Partnered Asset, Umbralisib (UKONIQ™), Has Received US FDA Accelerated Approval for Adult Patients With Relapsed or Refractory MZL & FL
- Rhizen Pharmaceuticals, a clinical-stage oncology-focused biopharmaceutical company, today announced that its novel next generation PI3K-delta inhibitor, Umbralisib, which was licensed to TG Therapeutics (NA...
- 2021년 02월 10일
-
- ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing
- ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that the U.S. Food and Drug Administration ...
- 2021년 02월 09일
-
- Takeda FY2020 Q3 Results Demonstrate Growth Acceleration and Continued Resilience; Full-Year Management Guidance for FY2020 Confirmed, Forecast Raised for Free Cash Flow and Reported EPS
- Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the third quarter of fiscal year 2020 (period ended December 31, 2020). TAKEDA CHIEF FINANCIAL OFF...
- 2021년 02월 08일
전시회
